Showing 15 posts of 89 posts found.


Second child cleared of leukaemia after Cellectis T-cell treatment

May 10, 2016
Manufacturing and Production, Research and Development cellecits, childhood, children, designer cells, leukaemia, rare, t cells, t-cells

A targeted T-cell oncology therapy has successfully treated a second baby with aggressive leukaemia who has remained in remission after …


FDA grants priority review for Amgen leukaemia drug

May 4, 2016
Research and Development, Sales and Marketing Amgen, FDA, blincyto, leukaemia, lymphoblastic leukaemia, paediatric

Amgen has announced that the US Food and Drug Administration (FDA) has granted priority review status for the supplemental Biologics …


MSD teams up with Harvard to develop new leukaemia treatments

March 24, 2016
Medical Communications, Research and Development AML, Harvard, MSD, leukaemia

MSD has entered a new collaboration with Harvard University aimed at developing innovative new small-molecule therapeutics for leukaemia and other …

Vidaza product image

Celgene’s Vidaza earns wider approval

November 2, 2015
Sales and Marketing Celgene, European Commission, Vidaza, acute myeloid leukaemia, azacitidine, leukaemia

Swiss firm Celgene has been given approval by the European Commission to extend its marketing authorisation for the cancer treatment …


NICE approves first in new class of leukaemia drugs

September 24, 2015
Cancer Drugs Fund, Gilead Sciences, NHS, NICE, idelalisib, leukaemia, zydelig

NICE has issued final draft guidance which recommends that Gilead’s Zydelig should be made available on the NHS for some …


NHS restriction of CML treatment in England criticised

August 27, 2015
Medical Communications, Sales and Marketing NHS, NICE, chronic myeloid leukaemia, leukaemia

Medical experts have criticised NHS cost regulators’ decision to limit the use of Ariad’s Iclusig (ponatinib) in the treatment of …

Abbvie and Roche report success in Phase II leukaemia trial

August 13, 2015
Research and Development AbbVie, Breakthrough Therapy Designation, CLL, EMA, FDA, Roche, chronic lymphocytic leukaemia, leukaemia, venetoclax

AbbVie plans to submit regulatory applications for its leukaemia drug venetoclax to the FDA and the EMA before the end …

Roche logo

NICE signs-off Roche’s Gazyvaro for leukaemia

June 2, 2015
Sales and Marketing Allergan, Bayer, CLL, Carole Longson, Eylea, Gazyvaro, NICE, Ozurdex, Roche, diabetic macular edema, leukaemia

NICE has given positive final guidance backing the use of Roche’s Gazyvaro for people with chronic lymphocytic leukaemia (CLL). Earlier …

arzerra image

Trial results back NICE decision on Novartis cancer drug

April 15, 2015
Sales and Marketing Arzerra, Cancer, NHS, NICE, chemo, chlorambucil, fludarabine, leukaemia, ofatumumab

Treatment with Arzerra improves survival in people with chronic lymphocytic leukaemia (CLL) according to study results that back NICE’s decision …

Amgen image

Speedy FDA nod for Amgen leukaemia drug

December 5, 2014
Research and Development, Sales and Marketing B-cell lymphoblasts, FDA, Kyprolis, blinatumomab, blincyto, leukaemia

The FDA has approved Amgen’s Blincyto (blinatumomab) to treat patients with Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukaemia (B-cell ALL). …

Roche image

NICE U-turn on Roche leukaemia drug

December 2, 2014
Sales and Marketing Gazyvaro, MabThera, NHS, NICE, Roche, leukaemia, obinutuzumab

NICE has reversed its decision on Roche’s chronic lymphocytic leukaemia (CLL) drug Gazyvaro only two months after rejecting the drug. …

GSK image

NICE backs GSK’s leukaemia drug Arzerra following price cut

November 4, 2014
Sales and Marketing Arzerra, CLL, GSK, NHS, NICE, leukaemia

NICE has recommended that GlaxoSmithKline’s Arzerra be prescribed under the NHS for patients with chronic lymphocytic leukaemia (CLL), after a …

Roche image

Roche and Pharmacyclics agree leukaemia pact

October 17, 2014
Research and Development, Sales and Marketing BMS, CLL, Cancer, Gazyva, Pharmacyclics, Roche, imbruvica, leukaemia

Pharmacyclics’s cancer drug Imbruvica will be tested in combination with Roche’s Gazyva in a new partnership announced by the firms. …

Iclusig image

EMA keeps Ariad cancer drug on the market

October 13, 2014
Sales and Marketing Ariad, CML, EMA, PRAC, iclusig, leukaemia, ponatinib

The EMA has recommended Ariad’s leukaemia drug Iclusig (ponatinib) should continue to be used under its current indication despite ongoing …

Boehringer blood cancer drug scores in Phase II

July 9, 2014
Research and Development, Sales and Marketing Boehringer, blood, giotrif, leukaemia, volasertib

Less than a year after securing its first cancer drug on the market with Giotrif, Boehringer has taken another decisive …

Latest content